Columbia Respiratory Critical Care Trials Group

Location and Contact Information

622 W 168th St, PH8-101
New York, NY 10032
United States

Principal Investigator

  • Profile Headshot
    • Director of Clinical Research, Center for Acute Respiratory Failure
    • Director of Columbia Respiratory Critical Care Trials Group

The two-part mission of our trials group is (1) to provide critically ill patients access to promising candidate therapies under study in clinical trials; and (2) to advance clinical interventions that improve survival and decrease morbidity from critical illness.

Our multidisciplinary team of clinician investigators has particular expertise in design and conduct of clinical trials in acute respiratory failure. We also participate in trials evaluating promising interventions for other critical illnesses routinely encountered in our intensive care units, and in cohort studies that aim to inform advancements in patient care. We have experience in FDA-regulated research, investigational drug and medical device trials, and have conducted trials sponsored by the U.S. National Institutes of Health, Department of Defense, industry, and non-profit foundations.

Our work is deeply rooted in the concept of research as service, to facilitate access to promising therapies. Our team spans both Columbia University Irving Medical Center (CUIMC) and NewYork-Presbyterian Allen Hospital and provides access to trials at both hospitals wherever possible. We work closely with patients, their families, and the treating clinical teams to help each individual decide whether participation is right for him/her, and we continue that partnership throughout the study period toward the shared goal of achieving expeditious recovery from critical illness.

We thank the many patients and families who have participated in clinical trials and other research with our group at Columbia. Your participation has improved patient care and outcomes from critical illness. We are incredibly grateful for your support.


Active Projects

Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) 3b Trial Therapeutics for Severely Ill Inpatients With COVID-19 (TESICO)

  • Sponsor: NIH
  • Details: Multicenter phase III platform trial evaluating safety and efficacy of promising potential therapies for patients with acute respiratory failure due to COVID-19. Currently, the trial consists of a 2x2 factorial design comparing aviptadil/placebo and remdesivir/placebo.

I-SPY COVID: An Adaptive Platform Trial for Critically Ill Patients

  • Sponsor: Quantum Leap Healthcare Collaborative
  • Details: Multicenter phase II adaptive platform trial evaluating safety and efficacy of promising potential therapies for patients with acute respiratory failure due to COVID-19.

Frequency of Screening and SBT Technique (FAST) Trial

  • Sponsor: Canadian Institutes of Health Research and Unity Health Toronto
  • Details: Multicenter phase III trial evaluating frequency and technique of spontaneous breathing trials to facilitate liberation from invasive mechanical ventilation.


Lab Members